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Abstract
Background: Metastatic renal cell carcinoma (RCC) remains the leading cause of mortality in
patients with clear cell RCC arising from mutations in the von Hippel Lindau (VHL) tumor
suppressor. Successful RCC tumor suppression by VHL requires the negative regulation of hypoxia
inducible factor alpha (HIF alpha) protein and its downstream targets. Thus, identification of HIF
target genes responsible for RCC tumor progression will aid in the development of therapies for
this disease. We previously identified membrane type-1 matrix metalloproteinase (MT1-MMP) as a
transcriptional target of HIF-2alpha in RCC cells null for VHL and showed that MT1-MMP is
overexpressed in these cells. MT1-MMP is a key regulator of tumor progression through its
functions as a matrix-degrading enzyme, as well as its ability to cleave factors, such as adhesion
molecules and other MMPs. The aim of this study was to investigate the contribution of MT1-MMP
to the invasive potential of RCC cells using in vitro type I collagen degradation and invasion assays.
Results:  We evaluated RCC cells wild-type (WT8) and null (pRc-9) for VHL for invasive
characteristics and showed that the pRc-9 cells demonstrated a greater propensity for both
invasion and degradation of a type I collagen matrix. Furthermore, overexpression of either HIF-
2alpha or MT1-MMP in the poorly invasive cell line, WT8, promoted collagen degradation and
invasion of these cells. Finally, using RNAi, we show that inhibition of MT1-MMP suppresses tumor
cell invasion of RCC cells.
Conclusion: Our results suggest that MT1-MMP is a major mediator of tumor cell invasiveness
and type I collagen degradation by VHL RCC cells that express either MT1-MMP or HIF-2alpha. As
such, MT1-MMP may represent a novel target for anti-invasion therapy for this disease.
Background
Kidney cancer represents ~3% of cancer deaths worldwide
and is the most deadly of the common urological diseases
[1]. While combined nephrectomy and immunotherapy
are standard care for localized primary renal cell carci-
noma (RCC) tumors, approximately 30% of these treated
patients will eventually develop metastases [2]. Addition-
ally, one third of patients present with metastatic disease
at time of diagnosis of the RCC primary tumor [3]. Treat-
ment of metastatic RCC remains difficult primarily due to
the resistance of the tumors to adjuvant and immuno-
therapies [4]. With the median survival of metastatic RCC
patients being less than one year, investigation into more
effective anti-metastatic therapies is clearly warranted
[3,5-7].
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Renal cell carcinoma is classified into four histological
subtypes, including clear cell, papillary, chromophobe,
and collecting duct [2]. Almost 80% of sporadic RCC is of
the clear cell subtype and results from inactivation of the
tumor suppressor, von Hippel Lindau (VHL) [8]. Loss of
VHL function also manifests itself as a dominantly inher-
ited familial cancer syndrome, impacting several organ
systems [8,9]. Life expectancy is greatly reduced for ~40%
of VHL patients who develop RCC, most commonly due
to complications from metastatic disease [5,6,10,11].
The most well-characterized function of VHL is in control-
ling the oxygen-sensing mechanism of the cell through its
regulation of hypoxia inducible factor (HIF) alpha subu-
nits (1α,-2α,-3α) [10,12]. HIF is a heterodimeric tran-
scription factor consisting of two subunits, HIF-α and
HIF-β [13]. While the β-subunit of HIF is constitutively
expressed, the HIF-α protein is labile and detectable only
under hypoxic conditions or when VHL is inactivated
[8,13-15]. Under normoxic conditions, VHL negatively
regulates the levels HIF-α subunit through ubiquitin-tar-
geted protein degradation [16,17]. Thus, inactivation of
VHL in RCC is associated with increased levels of HIF-α
isoforms and a subsequent increase in hypoxia-inducible
genes, such as those involved in angiogenesis (VEGF,
PDGF), erythropoiesis (EPO), glycolysis (Glut1), cell
growth and survival (Cyclin G2, TGF-α), and cell migra-
tion (CXCR4), suggesting that the genes upregulated by
the VHL-HIF pathway are involved in the progression of
renal cell carcinoma [8,13,15].
Although the majority of VHL mutations abrogate the reg-
ulation of HIF-α protein, a few mutations exist that retain
the ability for VHL to regulate HIF-α, and these mutations
are not associated with the formation of RCC [9,18]. In
fact, expression of such a VHL mutant, which retains the
ability to negatively regulate HIF-2α, suppresses tumor
formation of VHL null RCC cells in vivo [18]. These results
demonstrate that successful tumor suppression in renal
cells depends on the proper regulation of HIF-2α rather
than on the presence of VHL. Further evidence suggests
that HIF-2α, rather than HIF-1α, is the VHL target respon-
sible for tumorigenesis [19]. Indeed, inhibition of HIF-2α
is required for tumor suppression by VHL in RCC in vivo
[20-22]. These findings illustrate the importance of under-
standing the various roles that HIF-2α targets play in renal
cell tumorigenesis.
Previously, we identified membrane-type 1 matrix metal-
loproteinase (MT1-MMP) as a target gene of HIF-2α in
RCC cells mutant for VHL [23]. MT1-MMP is a membrane
bound member of the family of zinc-dependent
endopeptidases known as the matrix metalloproteinases
(MMPs), which function in remodeling the extracellular
matrix (ECM) [24,25]. Due to their vast repertoire of sub-
strates and functions in normal cellular processes, MMPs
are strictly regulated to guarantee appropriate, homeo-
static proteolytic events [26,27]. Elevated levels of MMPs
have been linked to the invasive behavior of most human
cancers as well as to other characteristics of tumors
[25,26,28]. In addition to pericellular proteolysis of type I
collagen, MT1-MMP is known to control cell-ECM con-
tacts, localize to the leading edge of invasive cells, cleave
adhesion molecules, and activate latent MMP-2 and
MMP-13 [24]. As a result, MT1-MMP plays multiple roles
in tumorigenesis, including tumor invasion, regulation of
tumor cell growth, cell migration, and angiogenesis
[29,30]. Our previous data suggest that the loss of the VHL
tumor suppressor, and subsequent stability of HIF-2α,
leads to the induction of MT1-MMP expression in RCC.
Interestingly, MT1-MMP expression has been linked to
advanced stages of RCC [31,32].
Given the important role of MT1-MMP in the progression
of other cancers [24], we hypothesized that as a HIF-2α
target, MT1-MMP may play a role in the progression of
VHL-/- RCC tumor invasion to metastatic disease. A met-
astatic tumor cell must invade through two main extracel-
lular matrix barriers: interstitial collagen in the stromal
environment (comprised mainly of type I collagen) and
basement membrane (comprised primarily of type IV col-
lagen) [33]. Koochekpour et al. showed in vitro that VHL-
/- RCC cell invasion of type IV collagen is enhanced by the
addition of neutralizing antibodies to TIMPs (tissue
inhibitors of matrix metalloproteinases), the natural
inhibitors of MMP activity, thereby implicating a role of
MMPs in this invasion [34]. These authors also showed
that VHL mutant RCC cells overexpress the gelatinases,
MMP-2 and MMP-9, which function to degrade type IV
collagen found in basement membrane. In our previous
studies, we reported that MT1-MMP is the main type I col-
lagenolytic enzyme expressed by VHL null RCC cells, sug-
gesting that this enzyme may mediate RCC invasion of
type I collagen [23]. Therefore, in this report, we specifi-
cally investigated the role of MT1-MMP in VHL RCC
tumor cell invasion using in vitro assays to measure the
ability of the cells to degrade type I collagen and to invade
through a type I collagen matrix. Using gene overexpres-
sion studies and RNAi, our data directly link HIF-2α and
MT1-MMP expression to an invasive phenotype of RCC
cells, and targeted inhibition of MT1-MMP is required to
block this invasion. We conclude that MT1-MMP is the
primary mediator of both tumor cell invasion and degra-
dation of type I collagen in these RCC cells and may rep-
resent an effective target for the treatment of invasive renal
cell carcinoma.Molecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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Results
VHL expression inhibits invasive properties of RCC cells
In previous studies [23], we used human RCC cells
derived from a VHL null parental cell line (786-0), which
was stably transfected with the pRc/CMV vector expressing
a wild-type copy of VHL (WT8) or with the vector alone
(pRc-9) [16]. Notably, these cells only express HIF-2α and
do not express the HIF-1α isoform [17]. We determined
that the lack of VHL tumor suppressor activity stabilized
HIF-2α protein and increased MT1-MMP expression
through direct transcriptional transactivation by HIF-2α
(summarized in Table 1) [23]. These data provide a link
between the loss of VHL function and the overexpression
of an enzyme responsible for pericellular proteolysis of
type I collagen and the activation of pro-MMP-2
[23,35,36]. In addition, our studies showed that MT1-
MMP is the primary type I collagenolytic enzyme
expressed by the VHL null cells. MMP-2 and MMP-9,
which degrade type IV collagen in basement membrane,
are also upregulated in these cells [23,34]. Since meta-
static tumor cells must invade through both interstitial
collagen in the stromal environment and basement mem-
brane [33], we hypothesize that MT1-MMP may contrib-
ute to the invasiveness of renal cell carcinoma in the
context of VHL inactivation by mediating type I collagen
invasion.
To begin our investigations, we characterized the WT8 and
pRc-9 cells for differences in tumor cell invasion and
matrix degradation that would suggest a role for MT1-
MMP [24,30,35]. We first compared the ability of the WT8
and pRc-9 cells to invade through a type I collagen matrix
using a Transwell® insert assay system. Neither cell line
invaded towards serum-free media. However, the pRc-9
cells, mutant for VHL, invaded approximately twice as
effectively towards a serum chemoattractant when com-
pared to the WT8 cells (Figure 1A). These data suggest that
VHL expression suppresses tumor cell invasion through
type I collagen. In similar in vitro invasion assays using
Matrigel or type IV collagen, RCC cells mutant for VHL
were also shown to be more invasive than RCC cells
expressing wild-type VHL [34,37,38].
Invasive tumor cells have the ability to migrate and to
remodel the surrounding, restrictive ECM using enzymes,
such as MT1-MMP, for pericellular proteolysis [36,39]. To
ask whether the observed increase in cell invasion by the
pRc-9 cells involves increased matrix degradation, we
measured the ability of these cells to degrade a type I col-
lagen matrix using an in vitro collagen degradation assay.
This assay is based upon the fact that when a fibrillar col-
lagen gel is degraded by cells embedded in it, culture
medium is liberated. This medium can be recovered and
weighed, and the amount of medium liberated provides a
simple, but accurate, measure of matrix destruction
[40,41]. Indeed, we found that collagen degradation was
increased by approximately 25% (P < 0.005) in the VHL
null cell line, pRc-9, as compared to the WT8 cells express-
ing wild-type VHL, indicating that the lack of VHL func-
tion promotes type I collagen degradation (Figure 1B). A
similar increase in collagen degradation was observed in
the VHL null 786-0 parental line (data not shown).
Expression of HIF-2α or MT1-MMP is sufficient to increase 
the invasive potential of RCC cells wild-type for VHL
Although the most well-described function of VHL is the
negative regulation of HIF-α isoforms, VHL has many
HIF-independent functions as well, including assembly of
actin filaments [42], fibronectin matrix assembly
[38,43,44], regulation of PKC isotypes [37], and endocy-
tosis of FGFR1 [45]. Each of these VHL functions has been
implicated in either RCC cell migration (cell movement in
the absence of matrix) or invasion (cell movement
through a matrix). To test whether the increased invasion
and degradation of type I collagen observed in VHL null
cells was due to the overexpression of HIF-2α target genes
or to the loss of HIF-independent functions of VHL, we
overexpressed HIF-2α in the context of wild-type VHL.
Previously, we showed that transient overexpression of
pCMV-HIF-2α in the WT8 cells was sufficient to drive
transcription of a reporter construct containing HIF bind-
ing sites even in the presence of wild-type VHL [23].
Therefore, we introduced a pCMV-HIF-2α expression con-
struct into the WT8 cells by transient transfection and
measured the ability of these transfectants to degrade a
collagen matrix. As shown in Figure 2A, overexpression of
HIF-2α in the WT8 cells increased collagen degradation of
these cells by ~30% (P < 0.0001), similar to the difference
in collagen destruction between the WT8 and the pRc-9
cells (see Figure 1B). These results indicate that HIF-2α
expression is sufficient to increase the collagen-degrading
ability of cells that are wild-type for VHL, thereby suggest-
Table 1: Renal cell carcinoma cell lines
Designation Transfectant VHL status HIF-2α protein MT1-MMP levels*
786-0 none null stable +++
WT8 pRc/CMV-VHL wild-type not detectable +
pRc-9 pRc/CMV-empty null stable +++
* Petrella, et al. 2005
"+" and "+++" indicate relative mRNA expression levels between cell linesMolecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
Page 4 of 14
(page number not for citation purposes)
ing that the increased invasion and matrix degradation
measured in the pRc-9 cells may be due to aberrant
expression of a HIF target gene(s) rather than the dysregu-
lation of other VHL targets. These data support our
hypothesis that as a target of HIF-2, MT1-MMP may con-
tribute to VHL RCC tumor cell invasion.
To further test this hypothesis, we transiently transfected
an MT1-MMP expression construct (MTpc3SE) into the
WT8 cells and measured the ability of these transfectants
to degrade type I collagen. This experimental design
allowed us to study the effects of MT1-MMP expression on
collagen invasion in the context of wild-type VHL and
HIF-2α instability, thereby eliminating the contribution
of other factors related to VHL mutations. Increased
expression of MT1-MMP in the MTpc3SE transfected cells
was confirmed by real-time RT-PCR, and MT1-MMP
mRNA levels were approximately six-fold greater than the
empty vector control transfectants (Figure 2B). The differ-
ence in MT1-MMP levels in these transfectants is compa-
rable to the difference in endogenous MT1-MMP levels in
the WT8 and pRc-9 cells previously published [23]. Fur-
thermore, overexpression of MT1-MMP increased colla-
gen degradation of the WT8 cells by approximately 30%
(P < 0.0001; Figure 2C), again resembling the increase in
degradation measured in the pRc-9 cells as well as the
HIF-2α transfected WT8 cells (see Figures 1B, 2A). These
data indicate that MT1-MMP may be the HIF target gene
responsible for the increased collagen degradation by the
VHL mutant cells since, to our knowledge, no other HIF
target with the ability to cleave type I collagen has been
identified in these cells.
Next, we tested whether MT1-MMP expression was suffi-
cient to promote collagen invasion of the WT8 cells by
transient expression of the MTpc3SE construct in these
cells and measured the ability of the transfectants to
invade through a type I collagen matrix using the assay
system as described in Figure 1. Expression of MT1-MMP
in the WT8 cells increased collagen invasion approxi-
mately two-fold compared to empty vector transfected
cells, showing that exogenous MT1-MMP expression
alone drives the invasiveness of cells that retain VHL func-
tion (P < 0.005; Figure 2D). Importantly, the difference in
invasiveness between the WT8 transfectants mimics the
difference in collagen invasion observed between the WT8
and pRc-9 cells (see Figure 1A). Together with our previ-
ous finding that MT1-MMP expression is regulated by
HIF-2α in VHL null cells [23], our data suggest that one
mechanism by which VHL may inhibit tumor invasion is
by suppressing MT1-MMP expression through the nega-
tive regulation of HIF-2α protein.
Expression of VHL inhibits collagen invasion and degradation Figure 1
Expression of VHL inhibits collagen invasion and deg-
radation. A. Collagen invasion. WT8 and pRc-9 cells were 
cultured in serum-free media on top of type I collagen coated 
membranes in a Transwell® invasion assay system. The lower 
chambers contained either serum-free DMEM as a negative 
control or DMEM supplemented with 10% FBS as a chemoat-
tractant. At time of harvest, the non-invaded cells and colla-
gen matrix on top of the membranes were removed, and 
invaded cells on the bottoms of the membranes were stained 
with methylene blue. A representative picture is shown of 
cells invading towards serum-free versus serum-containing 
media. Cells were counted from 3 fields per sample at 100× 
and averaged. Values in the graph represent the average 
number of cells invaded towards serum from four separate 
experiments relative to WT8 cell invasion (mean+/-S.D.); P < 
0.05 (*). B. Collagen degradation. WT8 and pRc-9 cells were 
serum-starved overnight, harvested and then embedded in a 
mixture of type I collagen and serum-free DMEM for the col-
lagen degradation assay. The collagen gel was allowed to 
solidify and serum-free media was added to the top of the 
collagen gel. The overlying media was weighed 48 hours after 
time of plating, and collagen degradation was determined by 
the volume of media liberated from the collagen gel. Values 
represent the average μL of media released from three sam-
ples (mean+/-S.D.); P < 0.01 (*) and are representative of 
four separate experiments. Statistical analyses were per-
formed using the student's t-test.Molecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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Expression of HIF-2α or MT1-MMP in WT8 cells increases matrix degradation and invasion Figure 2
Expression of HIF-2α or MT1-MMP in WT8 cells increases matrix degradation and invasion. A. Collagen degrada-
tion. WT8 cells were transfected with either a control empty vector or pCMV-HIF-2α. Transfectants were serum-starved 
overnight, harvested and then embedded in a mixture of type I collagen and serum-free DMEM for the collagen degradation 
assay as in Fig 1. After 48 hours, the overlying media was weighed, and collagen degradation was determined by the volume of 
media liberated from the collagen gel. Values represent the average μL of media released from six samples (mean+/-S.D.); P < 
0.0001 (***). B. Quantitative real-time RT-PCR analysis of MT1-MMP mRNA expression in WT8 cells co-transfected with 
pCMV-eGFP and either a control empty vector or MTpc3SE. Values represent the average pg of MT1-MMP mRNA normalized 
to ng of GFP mRNA from three separate transfections (mean+/-S.D.); P < 0.0001 (***). C. Collagen degradation. WT8 cells 
were transfected with either a control empty vector or MTpc3SE. Transfectants were subjected to the collagen degradation 
assay as in Fig 1. After 48 hours, the overlying media was weighed, and collagen degradation was determined by the volume of 
media liberated from the collagen gel. Values represent the average μL of media released from six samples (mean+/-S.D.); P < 
0.0001 (***). D. Collagen invasion. WT8 cells were transfected with either an empty vector or MTpc3SE. Transfectants were 
subjected to a collagen invasion assay as described for Fig 1. At time of harvest, the non-invaded cells and collagen matrix on 
top of the membranes were removed and membranes stained with methylene blue. Cells were counted from 3 fields per sam-
ple at 100× and averaged. Values represent the average number of invaded cells from five separate experiments set as relative 
cell invasion of the empty vector transfectant (mean+/-S.D.); P < 0.005 (**). Statistical analyses were performed using the stu-
dent's t-test.Molecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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Inhibition of MT1-MMP is necessary to decrease invasive 
properties of RCC cells expressing MT1-MMP or HIF-2α
To extend these findings, we asked if MT1-MMP was nec-
essary for VHL RCC cell invasion of collagen using RNAi
to specifically inhibit MT1-MMP expression. We could not
use the pRc-9 cell line for these experiments due to the
sensitivity of these cells to transfection and subsequent
manipulations. Although expression of MT1-MMP was
effectively reduced by three different targeting siRNAs in
the pRc-9 cells (data not shown), once transfected, the
cells did not survive trypsinization and culturing on top of
collagen for use in the invasion assays.
Alternatively, we performed the siRNA experiments using
the WT8 cells transfected to express either MT1-MMP or
HIF-2α in order to mimic the ability of the pRc-9 cells to
degrade collagen (see Figures 1B, 2A, 2C). Specifically, we
co-transfected the WT8 cells with MTpc3SE and one of
three specific MT1-MMP siRNAs or a non-specific control
siRNA and measured MT1-MMP mediated collagen inva-
sion. GFP expression was used to measure transfection
efficiency and to track tumor cell invasion using FluoroB-
lok™ membranes as described below. A dose response
analysis showed that the concentration of siRNA oligos
that reduced MT1-MMP mRNA by >50% was 25 nM (data
not shown). The reduction in MT1-MMP protein levels by
the specific siRNAs was confirmed with an ELISA assay
and was >60% as compared to the control siRNA (P <
0.005; Figure 3A).
In addition to its function as a matrix-degrading enzyme,
MT1-MMP also acts as a cell surface receptor for pro-
MMP-2 and promotes MMP-2 activation [46-48]. Specifi-
cally, MT1-MMP, TIMP-2 and pro-MMP-2 exist in a trimo-
lecular complex at the cell membrane [48]. When MT1-
MMP levels are in excess of TIMP-2 and pro-MMP-2, a free
MT1-MMP molecule cleaves the propeptide sequence of
pro-MMP-2 (72 kDa), thereby generating the intermedi-
ate (69 kDa) form [49]. Fully active (67 kDa) MMP-2 is
achieved by either intermolecular autolytic cleavage or by
the activity of other enzymes [46,47,50]. WT8 cells express
low levels of MMP-2 as well as TIMP-2 [23,34]. To con-
firm that the reduction in MT1-MMP protein by siRNA
was reflected in an inhibition of MT1-MMP enzyme activ-
ity, we measured the presence of pro, intermediate, and
active forms of MMP-2 in the conditioned media collected
from the transfectants using gelatin zymography. Expres-
sion of MTpc3SE in the WT8 cells resulted in the presence
of the intermediate and active forms of MMP-2 (Figure
3B). Inhibition of MT1-MMP activity by each MT1-MMP
siRNA was demonstrated by the absence of the MMP-2
intermediate and active species in these samples as com-
pared to the media from the siRNA control transfectants
(Figure 3B). The only other MMPs constitutively
expressed by these cells in addition to MT1-MMP are
MMP-2 and MMP-9 [23]. Therefore, it is important to
note that the MT1-MMP siRNAs have no effect on the
expression levels of MMP-2 or MMP-9 as seen by the
unchanged levels of the bands representing these proteins
in Figure 3B, confirming the specificity of these siRNAs
against MT1-MMP.
Next, the ability of the siRNA transfectants to invade
through a type I collagen matrix was measured using a
similar in vitro invasion assay system described in the pre-
vious Figures. For these invasion assays, we used type I
collagen-coated FluoroBlok™ membrane transwell inserts.
FluoroBlok™ membranes block the transmission of light;
therefore, non-invasive cells are not detectable, whereas
invasive, pCMV-eGFP transfected cells can be counted by
fluorescence imaging. By only visualizing GFP-expressing
cells that have invaded, we could specifically quantitate
the number of transfected cells that had invaded collagen
while discounting the non-transfected cells. As before (see
Figure 2D), WT8 cells expressing exogenous MT1-MMP
displayed increased collagen invasion (P < 0.005; Figure
3C). Co-transfection of the control siRNA oligo had no
significant effect on this increased invasion by MT1-MMP,
whereas each of the three specific MT1-MMP siRNA oligos
inhibited collagen invasion of the MT1-MMP transfect-
ants by greater than 85% (Figure 3C). Taken together,
these data suggest that MT1-MMP is important for tumor
cell invasion by RCC cells.
We previously identified MT1-MMP as a target of HIF-2α
[23], and our current data show that expression of HIF-2α
in a wild-type VHL background induces the ability of the
RCC cells to degrade type I collagen (see Figure 2A).
Together these results suggest that the increase in collagen
destruction mediated by HIF-2α overexpression in the
WT8 cells is due to the induction of MT1-MMP expres-
sion. To test this hypothesis, we transfected the WT8 cells
with pCMV-HIF-2α and either the control siRNA oligo or
one of the three MT1-MMP siRNAs. As shown in Figure
4A, MT1-MMP protein levels were reduced by the target
siRNAs in the HIF-2α transfectants by at least 50%. To
ensure that the inhibition of MT1-MMP expression by the
siRNAs was not due to non-specific effects of the siRNAs
on HIF-2α protein levels, we measured HIF-2α protein in
the transfectants. The WT8 cells do not endogenously
express detectable levels of HIF-2α protein due to the
presence of VHL [17] as shown in the empty vector con-
trol (Figure 4B); however, HIF-2α protein is detectable in
these cells upon transfection of CMV-HIF-2α, and the
MT1-MMP siRNAs had no effect on HIF-2α protein. Next,
we employed the FluoroBlok™ invasion assay system
described for Figure 3C to measure the ability of these
transfectants to invade type I collagen. Inhibition of MT1-
MMP blocked HIF-2α mediated invasion of these RCC
cells by >90% (Figure 4C). To our knowledge, the onlyMolecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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Inhibition of MT1-MMP blocks RCC tumor cell invasion Figure 3
Inhibition of MT1-MMP blocks RCC tumor cell invasion. (A) and (B) WT8 cells were transfected for 48 hours with 
MTpc3SE and control or 3 specific MT1-MMP siRNA oligos. Each transfectant was additionally co-transfected with pCMV-
eGFP. Transfection efficiency was consistent among the transfectants and was approximately 50%. A. MT1-MMP protein 
expression in the transfectants as quantitated by an MT1-MMP ELISA activity assay. Values represent the average [ng/mL] MT1-
MMP of three transfections normalized to [μg/mL] total protein and are representative of three experiments (mean+/-S.D.); P 
< 0.005 (**) compared to control siRNA. B. Gelatin zymography of conditioned media from transfectants to measure the pres-
ence of active MMP-2. Cells were transfected overnight and then cultured in serum-free media to condition the media for 24 
hours. Conditioned media was concentrated before analysis of gelatinolytic activity. C. In vitro invasion assay using type I colla-
gen coated Fluoroblok™ membrane inserts. WT8 cells were transfected for 48 hours with a control empty vector, MTpc3SE 
alone, or MTpc3SE and control or 3 specific MT1-MMP siRNA oligos. Each transfectant was additionally co-transfected with 
pCMV-eGFP and transfection efficiency was approximately 50%. Transfectants were serum-starved overnight before culturing 
on top of the collagen coated membranes in serum-free media. The lower chambers contained DMEM supplemented with 10% 
FBS as a chemoattractant. Invaded cells were viewed by GFP fluorescence and counted from the entire membranes at 40×. Val-
ues represent the average number of invaded cells from three separate transfections set as relative invasion of the empty vec-
tor control and are representative of two experiments (mean+/-S.D.); P < 0.005 (##) compared to empty vector control; P < 
0.0005 (***) compared to control siRNA. Statistical analyses were performed using the student's t-test.
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other HIF-2α target gene identified in playing a role in
RCC tumor cell migration and invasion is the chemokine
receptor, CXCR4 [51]. No effect of the MT1-MMP siRNAs
on the expression of CXCR4 was detected in the HIF-2α
transfectants (data not shown); thus, HIF-2α mediated
cell invasion is blocked by specific inhibition of MT1-
MMP. Together, these data imply that MT1-MMP is the
HIF-2α target gene responsible for the increased tumor
cell invasion observed in VHL mutant RCC cells.
Discussion
Renal cell carcinoma cells that have lost VHL tumor sup-
pressor function lose the ability to negatively regulate
HIF-2α protein levels, thereby allowing HIF-2α protein to
accumulate and dimerize with HIF-β to form a functional
transcription factor [17]. Consequently, downstream tar-
gets of HIF, such as MT1-MMP, are constitutively tran-
scribed, and activation of these targets causes RCC tumor
formation in xenograph models [20-22]. Defining the
HIF-2 targets responsible for VHL null RCC tumor pro-
gression is important to understand the mechanisms of
renal tumor development. It is not yet known whether ele-
vated expression of MT1-MMP contributes to RCC tumor-
igenesis or progression to metastatic disease.
When compared to several of the secreted MMPs, MT1-
MMP and MT2-MMP are the only MMPs able to confer
collagen invasive capabilities to non-invasive cells,
thereby suggesting that pericellular proteolysis is critical
for tumor cell migration and invasion [52]. Furthermore,
specific inhibition of MT1-MMP in tumor cells overex-
pressing MT1-MMP is sufficient to suppress tumor cell
migration, invasion, proliferation, and metastasis [53-
55]. Recently, the importance of MT1-MMP in cancer pro-
gression has been demonstrated by the finding that over-
expression of MT1-MMP in non-malignant cells was
sufficient to drive tumorigenicity [56]. In keeping with
these findings, we previously described a mechanism of
MT1-MMP transcriptional upregulation in VHL mutant
RCC cells and hypothesized that MT1-MMP may play a
role in the invasion of renal cell carcinoma [23].
Here, we provide evidence supporting the importance of
MT1-MMP in the invasive properties of RCC cells. First,
our data show that RCC cells null for VHL (pRc-9) have a
greater propensity for collagen degradation and invasion
than RCC cells wild-type for VHL (WT8), suggesting that
the pRc-9 cells have increased invasive potential (Figure
1). Further, overexpression of HIF-2α or MT1-MMP was
sufficient to confer increased degradative and invasive
abilities to the WT8 cells in type I collagen (Figure 2).
Finally, inhibition of collagen invasion by WT8 cells
transfected to express either MT1-MMP or HIF-2α
required specific inhibition of MT1-MMP expression (Fig-
ures 3, 4). Importantly, collagen invasion of the HIF-2α
transfectants was almost completely abrogated (>90%) by
the MT1-MMP siRNAs, suggesting that MT1-MMP is the
HIF-2α target primarily responsible for collagen invasion
by these cells.
The process of matrix invasion by a tumor cell requires
both degradation of ECM components as well as cell
migration [39]. In the pRc-9 cells, migration may result
from the lack of VHL, which regulates migration through
various mechanisms, including the regulation of actin fil-
aments [42], integrin fibrillar adhesions [57], and endocy-
tosis of FGFR1 [45]. By performing siRNA experiments in
a wild-type VHL background, we determined that inva-
sion of the RCC cells was dependent on MT1-MMP rather
than on the dysregulation of other VHL targets, suggesting
that MT1-MMP may be responsible for RCC tumor inva-
sion in the stromal compartment.
Our siRNA studies showed that inhibition of MT1-MMP
expression prevented the activation of pro-MMP-2 as a
measure of functional inhibition of MT1-MMP (Figure
3B) [46-48]. Thus, it is plausible that MT1-MMP may also
contribute to RCC invasion of basement membrane
through its regulation of pro-MMP-2 activation since
MMP-2 degrades type IV collagen, the main component of
basement membrane [33]. Interestingly, expression
MMP-2 has been correlated with advanced stages of RCC,
and MMP-2 activity, along with histological grade, stage,
and T classification, has been identified as a significant
predictor of RCC clinical outcome [58-60].
Since the expression of the MT1-MMP siRNAs inhibited
the activation of pro-MMP-2 by MT1-MMP (Figure 3B),
our data does not exclude the possibility that MMP-2
activity may be required for type I collagen invasion by
these RCC cells. However, this situation seems unlikely.
Although MMP-2 has been shown to cleave fibrillar type I
collagen, its ability to do so is less effective than known
collagenases and requires a cell-free, TIMP-free system
[71], which was not the condition under which we per-
formed our experiments. In particular, the WT8 cells used
in the siRNA studies (Figures 3, 4) express TIMP-1 and
TIMP-2, as previously described [34]; thus, MMP-2 may
not cleave fibrillar type I collagen under our experimental
conditions. Further, the intermediate form of MMP-2, a
species generated only when MT1-MMP and TIMP-2 are
present at specific ratios, is predominant in these cells
(Figure 3C) [49]. Thus, it is unlikely that in our system,
MMP-2 is playing a substantial role in the type I collagen
invasion by these cells. Nonetheless, since MMP-2 activity
is dependent on MT1-MMP [46-48], we conclude from
our data that MT1-MMP is required for type I collagen
invasion by these RCC cells. Thus, we posit that MT1-
MMP may initiate local invasion by RCC tumors by pro-
moting both cell migration and invasion through cleavageMolecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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Specific inhibition of MT1-MMP blocks HIF-2α mediated RCC tumor cell invasion Figure 4
Specific inhibition of MT1-MMP blocks HIF-2α mediated RCC tumor cell invasion. A. MT1-MMP protein expres-
sion as quantitated by an MT1-MMP ELISA activity assay. WT8 cells were transfected for 48 hours with pCMV-HIF-2α and a 
control or 3 specific MT1-MMP siRNA oligos. Each transfectant was additionally co-transfected with pCMV-eGFP. Transfection 
efficiency was consistent among the transfectants and was approximately 50%. Values represent the average [ng/mL] MT1-
MMP of three transfections normalized to [μg/mL] total protein and are representative of three experiments (mean +/-S.D.); P 
< 0.005(**), P < 0.0005 (***) compared to the control siRNA. (B) and (C) WT8 cells were transfected for 48 hours with a 
control empty vector, pCMV-HIF-2α alone, or pCMV-HIF-2α and control or 3 specific MT1-MMP siRNA oligos. Each trans-
fectant was additionally co-transfected with pCMV-eGFP. Transfection efficiency was approximately 50%. B. Western blot 
analysis of HIF-2α protein from whole cell lysates of the transfectants. Actin was used as a loading control. C. In vitro invasion 
assay of the transfectants using type I collagen coated FluoroBlok™ membrane inserts as described in Fig 3. Invaded cells were 
viewed by GFP fluorescence and counted from the entire membranes at 40×. Values represent the average number of invaded 
cells from three separate transfections set as relative invasion of the empty vector control and are representative of two 
experiments (mean+/-S.D.); P < 0.05 (#),P < 0.005 (##) compared to empty vector control; P < 0.0005 (***) compared to con-
trol siRNA. Statistical analyses were performed using the student's t-test.Molecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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of adhesion molecules, such as CD44 and integrins, pro-
MMP-2, and by pericellular proteolysis of type I collagen
fibrils in the stromal environment [30,61]. Supporting
this hypothesis, MT1-MMP mRNA expression is increased
in invasive RCC tumors when compared to tumors that
remain localized [31].
Our experiments using HIF-2α expression in the WT8 cells
demonstrate that HIF-2α increased type I collagen inva-
sion despite the presence of wild-type VHL, and this
increased invasion was dependent on MT1-MMP (Figure
4C). Kurban et al. recently showed that HIF-2α expression
in a VHL wild-type background does not promote inva-
sion of Matrigel [38], a reconstituted basement membrane
mainly comprised of type IV collagen and laminin [62].
The authors concluded from their studies that invasion by
VHL mutant cells is mediated via a HIF-independent
mechanism, namely, by the loss of ECM assembly. In their
Matrigel invasion assays, Kurban et al. used the RCC cell
line, WTPA, which stably expresses a HIF-2α variant that
is not degraded by VHL in a VHL wild-type background
[20]. In their study, WTPA cells did not invade Matrigel as
effectively as VHL mutant cells. Importantly, the authors
showed that the more invasive cell lines expressed MMP-
2, whereas WTPA cells did not. In our previous studies, we
showed that pRc-9 and WTPA cells have stabilized HIF-2α
protein and high levels of MT1-MMP when compared to
WT8 cells [23]. Like Kurban et al., we found that MMP-2
expression in WTPA cells was similar to WT8 cells and
much lower than pRc-9 cells (data not shown), suggesting
that the mechanism of MMP-2 overexpression in pRc-9
cells may not be HIF-2α dependent. Furthermore, inva-
sion of Matrigel likely requires MMP-2 gelatinolytic activ-
ity through the degradation of type IV collagen, whereas
type I collagen invasion, as in our assays, may not require
MMP-2 activity. Taken together, we conclude that while
RCC cell invasion of Matrigel may be HIF-independent,
HIF-2α mediates type I collagen of RCC cells through the
regulation of MT1-MMP.
Conclusion
Metastatic renal cell carcinoma remains difficult to treat.
Although IL-2 and IFN-γ are the standard of care for these
patients, the response rate is very low [4,63]. The VHL-HIF
pathway is a well-defined link to clear cell renal cell car-
cinogenesis, and thus targeting this pathway may benefit
VHL RCC patients [64,65]. Many next-generation agents
currently in clinical trials for RCC are therapies targeting
proteins regulated by the VHL-HIF pathway, such as VEGF
and TGF-α [63,64,66]. We provide evidence supporting
an important role for MT1-MMP in VHL RCC tumor cell
invasion of type I collagen. We conclude that the loss of
VHL tumor suppressor function is mechanistically linked
to invasive behavior through the regulation of MT1-MMP,
thereby implicating MT1-MMP as a potential therapeutic
target for the treatment of invasive RCC.
Methods
Cell lines and cell culture
Cell lines were maintained in Dulbecco's Modified Eagle's
Medium (Mediatech, Inc., Herndon, VA) supplemented
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT),
penicillin [100 U/mL], streptomycin [100 μg/mL], and L-
glutamine and cultured at 37°C, 5%CO2. For serum-free
conditions, DMEM supplemented with lactalbumin
hydrosylate (2%), penicillin [100 U/mL], streptomycin
[100 μg/mL], and L-glutamine was used. The WT8 and
pRc-9 cell lines (kindly provided by William Kaelin,
Dana-Farber Cancer Institute, Boston, MA) represent sta-
ble subclones of the 786-0 renal cell carcinoma cell line
transfected with pRc/CMV-HA-VHL or pRc/CMV-empty,
respectively [16]. The 786-0 cell line (American Type Cul-
ture Collection (Manassas, VA) has a single VHL allele
harboring a frameshift mutation at codon 104 resulting in
a truncated, non-functional protein [16,67]. The WT8 and
pRc-9 cells were cultured under continuous selection with
the addition of [1 mg/mL] G418 sulfate. Cells were
washed with either Hank's Balanced Salt Solution (HBSS)
(Mediatech, Inc.) or 1× PBS (13.7 mM NaCl, 0.27 mM
KCl, 1.2 mM phosphate buffer, pH 7.4) (National Diag-
nostics, Atlanta, GA) as indicated in the different experi-
mental procedures.
Reagents and plasmids
The pCMV-HIF-2α expression construct containing full-
length cDNA of HIF-2α was a generous gift of Richard
Bruick (University of Texas, Southwestern Medical Center,
Dallas, TX) [68]. The MT1-MMP expression construct,
MTpc3SE, was a kind gift of Jouko Lohi (University of Hel-
sinki, Helsinki, Finland), and contains full-length MT1-
MMP cDNA downstream of a CMV promoter [69]. The
pCMV-eGFP expression construct is commercially availa-
ble from BD Biosciences (San Jose, CA).
Transient transfections
WT8 cells were plated in 6-well dishes at a density of 1.5
× 105 cells/well in DMEM+10% FBS in the absence of anti-
biotics or selection. At this density, the cells were ~90%
confluent the following day and ready for transfection.
Cells were then transiently transfected with 1 μg of DNA
using Lipofectamine 2000™ Transfection Reagent (Invit-
rogen, Carlsbad, CA) following manufacturer's instruc-
tions for at least 12 hours before being washed three times
with HBSS and switched to serum-free conditions for
additional time depending on the experiment. Transfec-
tion with an empty vector (pRc/CMV) was used as a con-
trol for mock transfected cells [23]. All transfections were
performed in triplicate. Separate plates of cells were trans-
fected with pCMV-eGFP to control for transfection effi-Molecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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ciency under the given conditions. Transfection efficiency
was determined as a percentage of GFP-expressing cells
counted from 3 fields of 3 separate transfections, and the
average transfection efficiency was approximately 50% in
all experiments. Cells were harvested for either 1) func-
tional assays as described under 'Collagen invasion assays'
or 'Collagen degradation assay', 2) total RNA using the
RNeasy kit as described under 'Real-time RT-PCR', or 3)
protein expression analyses as described under 'ELISA' or
'Immunoblotting'.
siRNA transfections
Three siRNA duplex oligoribonucleotides targeting the
MT1-MMP coding region (NM_604995) were designed
using the Block-iT™ RNAi Designer program from the Inv-
itrogen website. The Stealth™ RNAi Negative Control
Duplex (cat# 12935-300; Invitrogen, Carlsbad, CA) is a
proprietary non-targeting sequence with medium G/C
content, which is similar to the G/C content of the target
Stealth™ siRNAs. The target siRNA sequences are as fol-
lows:  siRNA(1): 5'-AAUUUGCCAUCCUUCCUCUC-
GUAGG-3';  siRNA(2): 5'-
AAGAGAGCAGCAUCAAUCUUGUCGG-3'; siRNA(3): 5'-
AAUGAUGAUCACCUCCGUCUCCUCC-3'. WT8 cells
were plated in 6-well dishes at a density of 1.5 × 105 cells/
well as described under 'Transient transfections'. The fol-
lowing day, cells were transfected with 0.5 μg of pCMV-
eGFP, 1 μg MTpc3SE or pCMV-HIF-2α, and 25 nM of
either the control siRNA or one of the MT1-MMP target
siRNAs using Lipofectamine 2000™ Transfection Reagent
(Invitrogen) following manufacturer's instructions for co-
transfection of plasmid DNA and siRNA oligos. Cells were
transfected in the presence of serum for 24 hours before
being washed three times with HBSS and switched to
serum-free conditions for an additional 24 hours. Trans-
fection efficiency was determined by GFP expression as
described above before the cells were harvested for either
protein expression or the collagen invasion assay as
described under 'Fluoroblok™ invasion assay'. The average
transfection efficiency was approximately 50% in all
experiments. An empty vector control (pRc/CMV) was
used to balance the amount of plasmid DNA in co-trans-
fections [23]. All transfections were performed in tripli-
cate.
Real-time RT-PCR
Total cellular RNA was purified using the RNeasy kit with
on-column DNase I treatment (Qiagen, Valencia, CA).
Reverse transcription and real-time PCR reactions were
performed using the Taqman Reverse Transcription Rea-
gent Kit and Syber Green Master Mix, respectively, follow-
ing the manufacturer's protocol and as described
previously (Applied Biosystems, Foster City, CA) [23]. For
each experiment, triplicate samples were obtained, and
the cDNA for each was assayed in duplicate using a MJ
Research DNA Engine Opticon thermal cycler. Data are
presented as the average pg of MT1-MMP mRNA per ng of
GFP mRNA and are representative of three or more exper-
iments. Standard curves were included in each assay.
Standards were prepared from serial log dilutions of plas-
mids carrying the appropriate cDNA as follows: MTpc3SE
plasmid, 10 pg-0.001 pg; pCMV-eGFP plasmid, 1 ng-
0.001 ng. Primer sequences are as previously published
for MT1-MMP [23] and for eGFP [41].
ELISA
The Matrix Metalloproteinase-14 (MMP-14) Biotrak
Activity Assay System (GE Healthcare BioSciences Corp.,
Piscataway, NJ), a quantitative measure of MT1-MMP
activity as a direct measure of MT1-MMP protein, was
used to analyze MT1-MMP protein expression. The assay
was conducted according to the manufacturer's protocol.
A standard curve ranging from [0.125 ng/mL] to [8 ng/
mL] was used to quantitate protein expression. Because
the assay is colorimetric and does not require quenching,
absorbance readings were taken at 6 hr, 9 hr, and 12 hrs
after incubation with the substrate. The data presented
represent the concentration of MT1-MMP in the samples
at the timepoint at which the sample values fit the stand-
ard curve most appropriately. Total protein from the
extracts was quantitated using the Bradford Assay (Bio-
Rad, Hercules, CA) and used to normalize the MT1-MMP
protein concentration in each sample.
Immunoblotting and antibodies
Whole cell lysates were harvested from transfection exper-
iments by washing the cells twice with cold 1× PBS, add-
ing 100 μL of SDS reducing buffer (60 mM Tris-HCl, pH
6.8, 2% SDS, 14.4 mM β-mercaptoethanol, 25% glycerol,
0.1% bromphenol blue), and boiling for 5 minutes. Pro-
teins were resolved by SDS-PAGE and electrotransferred
to Immobilon-P PVDF membranes (Millipore Corp., Bed-
ford, MA). Membranes were blocked with 5% milk in Tris-
buffered saline 0.1% Tween-20 at room temperature for
1–2 hours. Primary antibodies, HIF-2α polyclonal anti-
body, 1:1000 (Novus Biologicals, Littleton, CO) and actin
monoclonal antibody, 1:5000 (Oncogene, Cambridge,
MA), were diluted in blocking buffer and incubated with
the membranes at room temperature for 2 hours. Appro-
priate secondary antibodies were diluted in blocking
buffer and incubated with the membrane at room temper-
ature for 1 hour. Proteins were visualized by Western
Lightning Chemiluminescence Reagent (Perkin Elmer,
Boston, MA).
Gelatin Zymography
Transfectants were cultured in serum-free media for 24
hours, and conditioned media was concentrated approxi-
mately 30 fold using BioMax 30 K NMWL membrane
ultrafree filters (Millipore Corp., Bedford, MA) as perMolecular Cancer 2006, 5:66 http://www.molecular-cancer.com/content/5/1/66
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manufacturer's instructions. An equal volume of non-
reducing buffer (60 mM Tris-HCl, pH 6.8, 25% glycerol,
0.1% bromphenol blue) was added to the concentrated
media before being applied to a 10% SDS-PAGE gel
impregnated with [2.8 mg/mL] gelatin. After electro-
phoresis, the gel was washed two times for 30 min in 50
mM Tris-HCl (pH 7.5), 5 mM CaCl2, 5 μM ZnCl2, plus
2.5% Triton X-100 followed by an overnight incubation at
37°C in the same buffer without Triton X-100. Gels were
stained with Coomassie Brilliant Blue R-250 and then
destained in 20% methanol, 10% glacial acetic acid. Activ-
ity was detected as transparent bands. Recombinant
human pro-MMP-2 (R&D Systems, Minneapolis, MN)
was used as a control for gelatinolytic activity at [1 ng/μL].
Active MMP-2 was obtained by incubation with 20 μM 4-
Aminophenylmercuric acetate (APMA, Sigma, St. Louis,
MO) at 37°C for 45 min.
Collagen invasion assays
Transwell® invasion assay
Cells were serum-starved overnight before being har-
vested for invasion assays. Transwell® inserts (Costar, 24
mm, Corning, NY) with 8.0 μm pore polycarbonate mem-
branes were coated with 50 μL per cm2 growth area with
type I collagen diluted to [1 mg/mL] in serum-free DMEM.
Collagen was prepared from purified bovine type I colla-
gen (Cohesion Technologies, Palo Alto, CA) following
manufacturer's instructions. Briefly, collagen was neutral-
ized to pH 7.4 with the addition of 10× PBS and 0.1 N
NaOH. The collagen was allowed to gel on top of the
membrane at 37°C for 1 hour. Next, either DMEM+10%
FBS or serum-free DMEM was added to the lower chamber
as a chemoattractant. Cells were plated on top of the col-
lagen layer at a density of 3.0 × 105 cells per insert in
serum-free media. Cells were allowed to invade for 4–6
hours. At time of harvest, media in the upper chamber was
removed, and the upper surface of the membranes was
scraped with a cotton swab to remove the collagen gel and
remaining cells. The membranes were rinsed with 1× PBS
and then removed from the inserts using a scalpel. The
membranes were then stained with methylene blue and
destained with water. Stained cells were viewed using an
Olympus 1 × 50 inverted phase contrast microscope at
100× and counted from 3 fields. Pictures were taken with
an Olympus Q Color 3 camera.
FluoroBlok™ invasion assay
siRNA transfected cells were serum-starved for 24 hours
before being harvested for the invasion assay. HTS Fluor-
oBlok™ inserts (BD Falcon Labware, 6.5 mm, Franklin
Lakes, NJ) contain fluorescence blocking PET track-etched
membranes with 8.0 μm pores. This invasion system
allowed for real-time viewing of cell invasion without the
need to end the experiment and process the membranes.
The FluoroBlok™ membrane prevents the transmission of
light to cells on top of the membrane; thus, only invaded,
GFP-expressing cells invaded through the collagen-coated
membrane can be viewed. FluoroBlok™ membranes were
coated with 90 μL per cm2 growth area with type I collagen
diluted to [0.8 mg/mL] in serum-free DMEM. Collagen
was prepared from purified bovine type I collagen (Orga-
nogenesis, Inc., Canton, MA) and neutralized to pH 7.4
with a buffer containing 9.8% 10× EMEM, [200 nM] L-
Glutamine, 2% lactalbumin hydrosylate, 7.5% sodium
bicarbonate. The collagen was allowed to gel on top of the
membrane at 37°C for 30 min. Next, DMEM+10% FBS
was added to the lower chamber as a chemoattractant.
Cells were plated on top of the collagen layer at a density
of 2.1 × 104 cells per insert in serum-free DMEM. Invaded
cells were viewed by GFP fluorescence using excitation
from a 100 W Mercury lamp on an Olympus 1 × 50
inverted phase contrast microscope. Cells were counted
from entire membranes at 40×.
Collagen degradation assay
Cells were serum-starved for at least 8 hours before being
harvested for the assay. Cells were embedded as a mixture
of fibrillar collagen and media in a 12-well assay format.
Collagen was prepared from purified bovine type I colla-
gen (Cohesion Technologies, Palo Alto, CA) following
manufacturer's instructions. Briefly, collagen was neutral-
ized to pH 7.4 with the addition of 10× PBS and 0.1 N
NaOH. Next, 3.2 × 105 cells were mixed with 132 μL of
neutralized collagen, and serum-free media was added to
bring the total volume to 635 μL per well. The final con-
centration of collagen in the mixture was [0.5 mg/mL].
The collagen was allowed to gel for 1 hour at 37°C after
which 635 μL of serum-free media was added to the top of
the gel. Assays were harvested at 48 hours, and the overly-
ing media was removed and weighed. The specific gravity
of serum-free media was determined to be 1 mg/mL.
Therefore, collagen degradation is reported as the volume
of liberated media calculated by the difference of the
weight of total media removed and weight of the original
volume added (635 μg or 635 μL). This assay provides an
accurate measure of collagen degradation in vitro [40,41].
Statistical analysis
Statistical significance was calculated using the student's t-
test available online [70] and are represented as +/- stand-
ard deviation (S.D.) of the mean. Significance was
assigned to P values < 0.05.
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